7 February 2024 - NICE has published final evidence-based recommendations on the use of nivolumab with relatlimab (Opdualag) for the treatment of patients with advanced (unresectable or metastatic) melanoma.

Nivolumab with relatlimab is recommended as an option for the first-line treatment of patients 12 years of age and older with advanced (unresectable or metastatic) melanoma only if it stopped after two years of treatment, or earlier if the cancer progresses and BMS provides it according to the commercial arrangement.

Read NICE technology appraisal guidance